The present invention relates to a microwell device and method, and in particular, to a valved microwell array device designed for high throughput cell culture assays, to microvalve for use in the device, and to methods for making the valve and device.
There is a growing demand in the drug discovery and related fields for high throughput cell culture systems, that is, systems capable of supporting large numbers of cell-culture assays in parallel. For a variety of reasons, it would be desirable to conduct large-scale cell-culture assays in a microfluidics device having an array or microwells and microfluidics structure for populating and feeding the wells. One major advantage of microfluidic cell culture is the possibility to mimic in vivo conditions. Culture parameters such as medium flow rate, shear stress, Peclet number, Reynolds number, liquid/cell volume ratio, length scale, and cell density can be controlled to more closely match physiologic conditions. Continuous medium perfusion and “on-chip” monitoring ensure a stable environment for cells during observation. These factors should limit variations in cell behavior and improve the statistical power of experiments. It is also likely that by providing more in vivo-like culture conditions, cell behavior will be closer to physiologic conditions, making assay results more relevant for medical applications.
The potential advantages of a microwell array device have been realized to a rather limited extent only in the prior art. Various limitations associated with prior art devices include (i) the requirement for bulky robotics to populate the wells in the device, (ii) difficulty in preventing microfluidics structures from being blocked by cell growth within the structures, (iii) inability to sustain uniform culture conditions over an extended assay period, (iv) inability to achieve and alter cell-culture conditions at the level of individual wells, and (v) difficulty in creating the necessary microfluidics structures efficiently by microfabrication.
It would therefore be desirable to provide a microwell array device capable of more fully realizing the advantages noted above in a high throughput cell culture system. There is also a need to achieve these advantages in a microfluidics device that can be constructed efficiently by microfabrication.
In one aspect, the invention includes a valved microwell device composed of a substrate having formed therein, a microfluidics passageway having (i) a microwell for receiving particles, such as cells therein, (ii) an inlet channel segment, (iii) an outlet channel segment, (iv) a channel intersection segment having a first channel arm that communicates the inlet and outlet channel segments, and a second channel arm communicating the inlet channel segment with the interior of the well, where the first channel arm flows around a portion of the well, and (v) a porous barrier through which fluid, but not cells, in the well can perfuse from the well into the first arm.
A microvalve disposed in the second channel arm is operable to control the flow of fluid from the inlet channel segment into the well, such that a cell carried in a fluid moving through the inlet segment can be diverted into the well by opening the valve, and once diverted into the well, can be captured therein, with fluid flowing through the passageway, by closing the valve, and culture medium flowing through the first arm can exchange solute components with culture medium within the well by diffusion of such components across the porous barrier. The microvalve may have the construction described below.
The device may further include another microvalve disposed in the first channel arm, operable to control the flow of fluid from the inlet channel to the outlet channel. The first channel arm may have a pair of branches that flow around opposite sides of the well, and the other valve may include a pair of valves controlling fluid flow through each branch.
The device may include a plurality of such passageways, a microchannel well-distribution network for supplying input fluid to each of a selected one or more of wells in the passageways, under the control of a plurality of valves associated with the network, and first and second valve-supply networks for supplying fluid pressure to the first and second microvalves, respectively.
In still another aspect, the invention includes a microarray culture system, including a microarray device having a substrate, and formed in the substrate, a plurality of microfluidics passageways, each having (i) a well for receiving particles, such as cells therein, (ii) an inlet channel segment, (iii) an outlet channel segment, (iv) a channel intersection segment having a first channel arm that communicates the inlet and outlet channel segments, and a second channel arm communicating the inlet channel segment with the interior of the well, where the first channel arm flows around a portion of the well, and (v) a porous barrier through which fluid, but not cells, in the well can perfuse from the well into the first arm. Associated with each passageway is a first microvalve disposed in the first channel arm for controlling the flow of fluid from the inlet channel segment into the first channel arm, and a second microvalve disposed in the second channel arm for controlling the flow of fluid from the inlet channel segment into the passageway well.
A microchannel well-distribution network in the device is operable to supply input fluid to each of a selected one or more of wells in the passageways, under the control of a plurality of valves associated with the network, and first and second microchannel valve-supply networks are operable to supply fluid pressure to first and second valves in the passageways, respectively. A plurality of reservoirs is each in fluid communication with a channel in the well-distribution network or in the valve-supply network. A controller in the system operates for supplying pressurized fluid to selected ones of the reservoirs, thereby to supply fluid to a selected one or more of the microfluidic passageways and to selected valves.
In a system containing N passageways, the microchannel distribution network may have X separate valved channels, where X=2 log2N. The first and second valve-supply networks may operate to supply fluid pressure simultaneously to all of the first valves, and to all of the second valves, respectively.
The system may further include a detector by which the presence or absence of cells in a passageway intersection can be determined, and a controller for sequentially activating the second and first valves for capturing a cell in such intersection in the associated well.
The reservoirs in the system may have at least one cell reservoir for holding cells to be introduced into the passageways, and at least one reagent reservoir for holding a solution to be perfused through the passageways. The system may further include a sample-control network for controlling the flow of fluid in the cell and reagent reservoirs to the well-distribution network.
The controller may operate in one mode to open the first valve, and close the second valve in each passageway, so that a cell-culture medium contained in a reagent reservoir flowing from a device inlet to a device outlet can exchange solute components with cell culture medium in each well across the porous barrier.
The controller may operate in another mode to close the first valve, and open the second valve of in each passageway, so that a medium flowing from a device outlet to a device inlet will carry the cells in the device wells out of the device.
In another aspect, the invention includes a valved microfluidics device having a substrate, a microchannel through which liquid can be moved from one station to another within the device, and a pneumatic microvalve adapted to be switched between open and closed states to control the flow of fluid through a microchannel. The microchannel is formed of (i) two or more flexible membranes forming wall portions in a valved region of the microchannel, including a primary membrane and one or more secondary membranes that are each joined to the primary membrane at a common edge, and (ii) a chamber formed in the substrate, separated from the microchannel by the primary membrane and adapted to receive a positive or negative fluid pressure, thus to deform the primary membrane. Deformation of the primary membrane causes the secondary membrane(s) to deform, and the combined deformation of the primary and secondary membranes is effective to switch the condition of the valve between its open and closed states.
The device may include, for each secondary membrane, a recess formed in the substrate into which the secondary membrane is deflected when deformed. The flexible membranes may include a top-wall primary membrane and a pair of opposite side-wall secondary membranes, with the valved region of the microchannel, with the valve in its open state, being substantially rectangular. The height to width ratio of the rectangular microchannel may be at least about 0.5 to 1.0. The application of positive pressure to the chamber, to place the valve in its closed state, may cause the primary membrane to bow outwardly into the channel, and the secondary membranes to bend outwardly at their common edges with the primary membrane, into the associated recesses, thus to enhance the extent of sealing between the primary membrane and the two secondary membranes as the primary membrane is deformed.
The flexible membranes in the device may be formed of any elastomer that is compatible with microfabrication techniques, e.g., PDMS elastomer.
The microchannel in the device may intersect a channel segment, and the valve may be positioned in the channel segment to control the amount of fluid flow from the microchannel into the segment. The channel segment may connect the microchannel with a well formed in the substrate, where the valve is used to control the flow of fluid from the micro channel into the well.
In a related aspect, the invention includes a microfluidic device comprising an elastomeric monolith situated between a rigid substrate and a semi-rigid substrate. In one embodiment the two substrates are planar. In another embodiment the elastomeric body comprises multiple elastomeric layers separately prepared and having defined in a first surface of each layer a pattern of channels and/or chambers. The separate layers are bonded together to form the monolith such that the microfluidic features (e.g. channels, chambers, etc.) defined in the surface of one layer are sealed off against the surface that lacks microfluidic features of a different layer. Preferably, the different layers contain features that operate in conjunction with those of another layer. When bonding the layers, the features of each layer are aligned such that they operate in conjunction with one another. Preferably, an adhesion promoter is used to bond the semi-rigid substrate to the elastomeric monolith.
In one embodiment the microfluidic device is prepared by combining a first elastomeric layer having microfluidic channels in a first surface and a second elastomeric layer having pneumatic control chambers in a first surface to form an elastomeric monolith. The monolith is characterized by having microfluidic channels disposed in a first surface and pneumatic control chambers disposed within the body of the monolith. Access holes providing communication from the external world to the channels and chambers are also provided through both of the substrates and the monolith.
In yet another aspect, the invention includes a method for fabricating a valved microfluidics device of the type described above. The method includes, in part, the steps of preparing a mold having a fluorocarbon surface coating, dispensing an elastomeric precursor over the coated mold; at least partially curing the elastomeric precursor and removing the at least partially cured elastomer from the mold. The method also further includes, in part, placing the side of a semi-rigid sheet coated with an adhesion promoter on top of the elastomeric precursor prior to the step of at least partially curing the elastomer, and after the curing step, removing the joined semi-rigid sheet and elastomer from the mold.
In one embodiment of a method for fabrication of a multilayer microfluidic device, two molded elastomeric layers are formed, joined together and bonded to a substrate. A first mold is prepared having an upper layer fluidic design, and a second mold is prepared having a lower layer fluidic design. Preferably, the molds have a fluorocarbon surface coating. After an elastomer precursor is dispensed over the first and the second molds, the side of a semi-rigid sheet coated with an adhesion promoter is placed on top of the elastomer precursor spread on the first mold. The elastomer precursors are at least partially cured. Thereafter the joined semi-rigid sheet/elastomer unit is removed from the first mold, and the molded surface of the unit is placed over and aligned with the elastomer residing on the second mold. The two elastomer surfaces are bonded together, and the elastomers are fully cured during or following bonding. Thereafter the bonded elastomer assembly is removed from the second mold. The molded surface of the lower layer is bonded to a rigid substrate, thereby enclosing the features of the molded surface of the lower layer.
In yet another aspect, the invention includes a method of fabricating a microfluidic device comprising (a) an elastomer monolith and (b) a holder for both securing the monolith and providing ports for addressing the fluidic features of the monolith with external fluids and/or removing fluids from the monolith. The fabrication method comprises (a) preparing a module comprising an elastomeric monolith having on one face a semi-rigid thermoplastic substrate adhered thereto, with ports through the semi-rigid substrate accessing a microfluidic network formed in the elastomeric monolith, (b) preparing a holder having on a first surface at least two recessed openings and having on the opposite surface a cavity, and openings within the cavity communicating with each of the recessed openings, and (c) bonding the semi-rigid substrate of the module within the cavity such that the ports of the module align with the openings in the cavity.
These and other objects and features of the invention will become more fully understood when the following detailed description of the invention is read in conjunction with the accompanying drawings.
A. Definitions
A “particle” refers to biological cells, such as mammalian or bacterial cells, viral particles, or liposomal or other particles that may be subject to assay in accordance with the invention. Such particles have minimum dimensions between about 50-100 nm, and may be as large as 20 microns or more. When used to describe a cell assay in accordance with the invention, the terms “particles” and “cells” may be used interchangeably.
A “microwell” refers to a micro-scale chamber able to accommodate a plurality of particles. A microwell is typically cylindrical in shape and has diameter and depth dimensions in a preferred embodiment of between 100 and 1500 microns, and 10 and 500 microns, respectively. When used to refer to a microwell within the microwell array device of the invention, the term “well” and “microwell” are used interchangeably.
A “microchannel” refers to a micron-scale channel used for connecting a station in the device of the invention with a microwell, or a station and a valve associated with the microwell. A microchannel typically has a rectangular, e.g., square cross-section, with side and depth dimensions in a preferred embodiment of between 10 and 500 microns, and 10 and 500 microns, respectively. Fluids flowing in the microchannels may exhibit microfluidic behavior. When used to refer to a microchannel within the microwell array device of the invention, the term “microchannel” and “channel” are used interchangeably.
A “microfluidics device” refers to a device having various station or wells connected by micron-scale microchannels in which fluids will exhibit microfluidic behavior in their flow through the channels.
A “microvalve” refers to a valve operable to open and close a microchannel to fluid flow therethrough. When used to refer to a microvalve within the microwell array device of the invention, the term “microvalve” and “valve” are used interchangeably.
A “microwell array” refers to an array of two or more microwells formed on a substrate.
A “device” is a term widely used in the art and encompasses a broad range of meaning. For example, at its most basic and least elaborated level, “device” may signify simply a substrate with features such as channels, chambers and ports. At increasing levels of elaboration, the “device” may further comprise a substrate enclosing said features, or other layers having microfluidic features that operate in concert or independently. At its most elaborated level, the “device” may comprise a fully functional substrate mated with an object that facilitates interaction between the external world and the microfluidic features of the substrate. Such an object may variously be termed a holder, enclosure, housing, or similar term, as discussed below. As used herein, the term “device” refers to any of these embodiments or levels of elaboration that the context may indicate.
B. Microarray Culture System and Device
A robotic arm 32 in the system is vertically shiftable on the tower to positions at which the arm can engage a selected plate, such as plate 27, remove the plate from its slot, rotate the engaged plate 180°, and vertically move the plate for placement on a horizontally movable x-y stage 35 of a loading and observation structure 34 in the chamber. When a plate is removed from a slot, and thus disconnected from the pressure supply lines from the solenoids, it may be connected to a manifold coupler 37 which couples the plate reservoirs to the respective solenoids, allowing activation of various valving functions used for loading cells into the microwell array device carried on the plate, when the plate is positioned on structure 34, as will be described below.
Structure 34 includes a microscope 36, camera 38, and an optical detector 40 for sensing the position of cells at selected locations on a microwell array chip supported on the plate, as will be described. As noted above, stage 35 is movable, in small x-y increments within the filed of the microscope, to position the chip carried on the plate at selected located within the field of view of the microscope.
Culture conditions within the chamber are maintained by air- and CO2-supply to the chamber and by heaters (not shown) within the chamber.
Also included in the system is a computer or processor 42, and keyboard 46 and monitor 44 for user input and program display. The computer is operatively connected to the detector and to the solenoids, such as solenoids 31, 33 for controlling gas pressure to the plate manifolds in accordance with the cell-loading and cell-culturing operations performed by the system, to be described below.
In operation, the reservoirs in a plate are covered by a leak-tight gasket (not shown) that serves as a manifold between the system solenoids and each plate. That is, the gasket contains a line for pressurized gas between each solenoid manifold and one of the reservoirs on the pressurized-gas line.
Passageway 62 in the device, which is representative, is illustrated in enlarged layout view in
Also shown in
As seen in
With particular reference to
Flow of medium from one of the three supply-reservoir stations to the well-distribution network is controlled by a pair of microvalves 106, 108 activated by fluid supply from station 18, and a pair of valves 104, 105 activated by fluid supply from station 17.
Flow of medium through the well-distribution network is controlled by coordinated activation of each of eight valve sets controlled by fluid supply from stations 4-11. Each valve set, such as valve set 110, includes eight individual microvalves, such as microvalves 112, that are arranged on the sixteen channels of the network in a binary pattern seen in the truth table in Table 4. Columns 4-11 in this figure represent the eight valve-control stations, rows 1-16 represent the 16 passageways, indicated A1-H1 and A2-H2, and the unfilled blocks indicates a microvalve at that position row and column in the network. The pattern of filled blocks in the table indicates the pattern of closed valves that will direct medium to a selected one of the 16 passageways. As seen, each passageway can be uniquely accessed by closing some combination of four valves. For example, the microchannel supplying fluid to passageway H1 has four microvalves at positions corresponding to stations 5, 7, 9, and 11. Thus, closing valves 4, 6, 8, and 10 will leave this channel free for fluid flow, while blocking all others. Similarly, the microchannel supplying fluid to passageway G1 has four microvalves at positions corresponding to stations 4, 7, 9, and 11. Thus, closing valves 5, 6, 8, and 10 will leave this channel free for fluid flow, while blocking all others. More generally, employing this binary-control scheme, an array of N microchannels can be individually accessed by X valve stations, each controlling N individual valves, where X=2 log2N.
With continued reference to
Completing the description of the device layout, and with reference to
In a preferred embodiment, and as will be described more fully in Section C below, the device is preferably formed as a microfabricated silicon wafer, and has side dimensions of between about 50 to 150 cm. Each reservoir in plate 26 is designed to hold between about 0.001 and 0.5 cc of fluid, e.g., liquid, and each microwell typically holds 1 to 100 nl. The microwells and microchannels in the device have dimensions as indicated above.
The following setup will illustrate plate preparation, cell loading, and incubation operations carried out in the system. For this illustration, it is assumed that three different media will be supplied to the microwells: a suspension of cells used in loading cells into each of the 16 microwells through station 1, and cell-culture media solutions containing two different drugs or different concentration of the same drug, each of which will be supplied to one of the two groups of eight microwells (A1-H1 and A2-H2 in
After filling the plate reservoirs with the above fluids, the reservoirs are covered and sealed with a gasket manifold that serves to connect each of the reservoirs to the associated solenoid valves. The plate is then moved to stage 35 in the system for loading each microwell in the device with cells. This loading procedure is carried out successively for each of the 16 microwells in the device.
The device is now in a condition for introducing cells into each of microwells. This is done, as indicated above, by selectively closing four of the eight sets of valves under the control of stations 4-11, to allow passage of fluid through the network to one passageway only.
With continued reference to
In the above-described operations, all of the pairs of first valves, and all of the second valves, are simultaneously activated from stations 15 and 16, respectively, as described above; thus, selective control of cells into any individual microwell is controlled at the level of the well-distribution network rather than by the valves controlling the movement of fluid within each passageway. This obviates the need for separate control over the valves in each passageway. Although the above cell-loading operations could be controlled by valving operations within each passageway, it will be appreciated that the well-distribution network offers a more efficient way of control fluid flow within each passageway. For example, in the present embodiment, controlling individual first and second valves in all 16 passageways would require 32 port stations rather than the 8+2 stations required with the configuration shown.
After loading each of the microwells with a selected number of cells, the device is switched to a cell-assay mode in which each of the microwells in the device are exposed to selected cell-culture assay conditions. As one example, assume it is desired to assay the cells in the two groups of eight wells with two different concentrations of the same drug. Cell culture media containing each of the drug concentrations are then placed in the reservoirs feeding port stations 2 and 3 in
Also during the assay period, valves 114 and 116 are maintained in an open conditions, allowing material being forced through the passageways to be collected at the reservoir services by port station 12.
At the end of the cell-assay periods, e.g., after a 1-2 day incubation period, material from the two sets of microwells may be collected into each of two collection reservoirs through stations 13 and 14. As seen in
Alternatively, where the cell assay involves inhibition or stimulation of cell growth, or uptake by the cells of a fluorescent material, the cells in the wells in each device may be inspected periodically, by removing a selected plate from tower 28 in
C. Valved Microfluidics Device and Microvalve
This section will describe the construction and operation of a microvalve in accordance with one aspect of the invention, and a valved microfluidics device employing one or more such microvalves. The microvalve is suitable for use in the array device already described, and the microfluidics device may contain one or more valved microwell passageways of the type described above.
D. Microfabrication Methods
In order to more clearly focus on illustrating the fabrication process, the microfluidic pattern 1310 is a simplified pattern, yet one that includes enough features to provide for a valved microfluidic device of the type discussed above. As exemplified in the figure, an inlet area 1312 and an outlet area 1314 are provided for access with the external world. Inlet channel segment 1316 leads from the inlet area 1312 to an intersection with a pair of first arm channels 1320a and 1320b, and second arm channel 1322. The pair of first arm channels 1320a and 1320b later merge downstream and lead into outlet channel segment 1328, which ends at outlet area 1314. Second arm channel 1322 leads into well 1324. The well 1324 communicates with the first arm channels via a series of smaller passageways 1326 connecting the two features.
The pattern in the microfluidic layer also includes the recesses of the valve regions in the first and second channel arms. The recesses 1330a and 1330b are defined on either side of each of the first arm channels 1320a and 1320b, respectively. Likewise the recesses 1332 flank the second channel arm 1322. The recesses are voids into which the side walls of the channels (secondary membranes) may deflect when the pressure is changed at the primary membrane, and thereby operate as part of the valve. The recesses thus serve to define the valve region of the channel, although to be functional the primary membrane needs to also be provided at the same region. Note that the primary membrane is defined through the fabrication of the pneumatic control layer, described in
First, the microfluidic passageways 1326 that connect the well 1324 with the first arm channels 1320a and 1320b are defined on the substrate using standard photolithography techniques. These passageways, also referred to as perfusion channels, are of a smaller height, and thus are defined first, in a step separate from the other fluidic channels and wells. Photoresist is spun onto the wafer 1300, softbaked, and the wafer is irradiated through a reticle defined with the pattern as shown in the plan view of
Next, the wafer surface is etched away using a dry etching process to leave raised portions that define the perfusion channels 1326. Approximately 1 μm of the surface is etched away using a SF6 plasma. For example, using a PlasmaTherm PK-12 RIE, at an RF power of 100 W and a chamber pressure of 60 mTorr, the etch is performed for two minutes. The resulting wafer is illustrated in the cross-sectional view of
With the photoresist in place, the remainder of the wafer surface is etched away (
Finally, the microfluidic layer mold is completed by coating the processed wafer with a fluorocarbon layer, as shown in
As exemplified in
The fabrication process follows that already described in conjunction with
The exposed wafer surface is etched away using a dry etching process to leave raised portions that define the control channels (1414a, 1414b, 1424) and chambers (1416a, 1416b, 1426). Approximately 5 μm of the surface is dry etched away using a SF6 plasma, using the PlasmaTherm PK-12 RIE, at an RF power of 100 Wand a chamber pressure of 60 mTorr, for ten minutes. The resulting wafer is illustrated in the cross-sectional view of
Finally, the control layer mold is completed by coating the processed wafer with a fluorocarbon layer, as shown in
Preferably sheet 1500 is approximately 1.5 mm thick, such that it maintains a two-dimension rigidity. The sheet is to perform (1) as a backing for the elastomer parts to (a) make handling easier and (b) prevent tearing, and (2) as a surface for bonding the elastomer device to a holder. Note that a thinner sheet may be used, but if the sheet no longer maintains a two-dimensional rigidity the above purposes will not be met. The sheet may be thicker, e.g. several mm's in thickness, or more, though at greater thicknesses the extra material becomes superfluous although not detrimental.
One surface of sheet 1500 is to be coated with an adhesion promoter 1510. The promoter is to aid in the bonding of the sheet 1500 to the molded elastomer part, and is needed because of the dissimilarity of the materials of the two parts. An exemplary adhesion promoter is the 1200 Primer (Dow Corning, Midland, Mich.), which is typically used to promote the adhesion of silicone materials to a variety of materials. This promoter is an appropriate choice given that the preferred elastomer is a silicone derivative, polydimethylsiloxane. Other promoters may be selected as appropriate for a given choice of materials for the sheet and the elastomer part, as are known to those skilled in the art of adhesives and bonding of plastics and elastomers.
The adhesion promoter is to be applied to the surface of the sheet just prior to use. Manufacturer's recommendations should be followed as to the timing of application prior to the bonding step for any promoter that is selected.
First, as shown in
To prepare the device layer elastomer, for example, Sylgard 184 is dispensed over the wafer with mold, 1600, and by spin-coating, a layer of the PDMS precursor 1610 is formed with a height of 70 μm. The height of elastomer ultimately obtained should be considered when determining the height of the precursor to be spread over the mold. For example, any shrinkage or contraction that might occur when the precursor is cured should be accounted for.
The height of the elastomer in relation to the height of the mold features determines the thickness of the membrane between the channel feature and the next layer of elastomer, the control layer, in the final assembly. In locations where the channel portion is to be the valve region, the membrane will be the primary membrane of the valve, and its performance and activation parameters will be determined by the thickness established in this step. A thickness of about 20 μm is preferable, though the thickness may reasonably vary. As one skilled in the art would know, a thinner membrane may not be as durable, but the valve would be capable of activation at lower pressure. Conversely, a thicker membrane would be more robust and durable, but would require greater operating pressures to be activated. Membranes thicker than about 100 μm generally require activation pressures that are high enough to damage the material. Furthermore the thickness makes it difficult to activate the valve into a fully closed position and thus is not preferred where complete closure of the valve is necessary.
After spin-coating the PDMS precursor, the material is partially cured by treatment in a 60° C. convective oven for one hour.
In parallel, the control layer elastomer part is prepared with a similar material.
The semi-rigid sheet described in
After preparing the assembly, the elastomer material is partially cured, again by treatment in a 60° C. convective oven for one hour.
The upper layer, the control device layer with the backing sheet 1650 is aligned over the device layer mold 1600 and molded part 1620 such that the operational features of the valves are properly positioned, and then contacted together for bonding. This process may be performed with the aid of a standard mask aligner, such as a Quintel Q-4000 Series mask aligner. The assembly now comprises the lower mold 1600, the device layer molded part, the control layer molded part, and the semi-rigid sheet, as shown by the cross-sectional view of
When the assembly has cooled to room temperature, the now joined sheet and bonded, cured elastomer 1684 is peeled off of the mold, as shown in
Next, access holes are formed in the device 1686 by piercing, drilling, ablating, or laser cutting. The access holes are bored through the entire height of device 1686. The location of the access holes correspond to the areas designated as the inlet areas or outlet areas of each of the two layers. Referring to the plan view drawing of
The holes are preferably formed by laser cutting techniques. The laser may be either a continuous wave (CW) mode or pulsed mode type. Although greater care must be used when cutting with a CW laser because of the possibility of overheating or charring the material, operation with CW lasers is possible so long as the device is no thicker than several millimeters. For example, a VersaLaser, from Universal Laser Systems (Scottsdale, Ariz.), operated at 25 W and controlled to move at 40% arm speed over steps of 1000 points per inch to cut the access holes successfully bores holes through devices comprising a 1.5 mm sheet and a ˜300 μm elastomer monolith. The holes are cut by controlling the laser to follow a circular pattern around the center point of the hole location via the software controls provided with the instrument. If a thicker device undergoes charring during laser cutting with a CW laser then operation with a pulsed mode laser is preferred.
The bottom surface of device 1686, bearing the molded imprint of the fluidic device layer, is next bonded to a rigid substrate to enclose the channels and chambers of the fluidic layer, as well as to seal off the bottom of the access holes. The substrate preferably contains surface hydroxyl groups to make the surface amenable to bonding with the elastomer material. For example, substrates such as glass, metal oxides, silicon with an oxide surface are suitable, providing both rigidity and the necessary affinity for bonding to the elastomer.
The device assembly 1698 is fully capable of use as a microfluidic device with functioning pneumatically controllable valves. For greater ease of use and to enable interfacing the device with automated robotic systems, the device 1698 may be integrated with a housing or a holder that facilitates putting reservoirs of fluids in communication with the device, and connecting fluid lines and pneumatic controls to the device. When low pneumatic pressure is required, gravity-driven flow can be used by tilting the device 1698.
The holes may be shaped for a variety of special purposes. For example, where the hole is to be used as a liquid reservoir, the hole may be dimensioned to be that of a standard microwell plate, e.g. a 96-well plate or a 384-well plate or other sizes. The standard sizes are set forth in the SBS standards and can be found on www.sbsonline.org/msdc/pdf/text1999-04.pdf. Also, the holes themselves may be positioned relative to one another at standard distances that conform to SBS standards. The purpose of using standardized well shapes and distances is to facilitate interfacing the part with automated dispensing and handling systems. The hole may also function as a connection port, e.g. for receiving the tips, couplers or connectors of fluid (liquid or gas) lines. There are numerous standard interfaces for such connections, and any of these may be employed in the design of the part. One common example of a connection is a Luer connector, though many others are possible. The hole, shaped as a Luer receiver, would permit the rapid insertion of a Luer-tipped syringe body. Note also that the various holes may be prepared with differently shaped or sized holes, depending on the purpose of the hole and the underlying access hole in the fluidic device with which it communicates.
The part itself may be made of any suitable durable material, with metal or plastic being preferred. The part may be machined, cast or molded, according the material type chosen. Molded plastic parts are preferred for their low cost. Standard injection molded methods are suitable for making the part, being able to provide the necessary precision and detail of shape desired.
As shown in
Note that the number of holes in the upper part generally correspond to the number of access ports formed in the fluidic device (e.g. 1698). The holes in the upper part 1700 communicate with the access holes, but are generally not positioned directly vertically above the access holes, although if the space permits they may be so positioned. Often, due to the density of access holes in the design, the larger holes used in the holder 1730 need to be offset from a position vertically above the access holes. The two-part holder design shown in
The last step in assembling the integrated microfluidic device is shown in
The design of the microfluidic device used to illustrate the fabrication process was simplified for the ease of presentation and explanation. The steps used in the process are generally applicable to a wide variety of device configurations, including devices of much greater size, complexity and density, as would be appreciated by those skilled in the art of fluidic device design and fabrication. For example, the devices described throughout this disclosure are all capable of fabrication by these methods.
This patent application is a continuation of U.S. patent application Ser. No. 13/602,328 filed Sep. 4, 2012, (now U.S. Pat. No. 8,673,625, issued Apr. 11, 2013) which is a divisional of U.S. patent application Ser. No. 11/648,207 filed Dec. 29, 2006 (now U.S. Pat. No. 8,257,964, issued Sep. 4, 2012), which claims priority to U.S. provisional patent application No. 60/756,399 filed on Jan. 4, 2006, which is incorporated in its entirety herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4055613 | Kapral | Oct 1977 | A |
4661455 | Hubbard | Apr 1987 | A |
4734373 | Bartal | Mar 1988 | A |
4748124 | Vogler | May 1988 | A |
5079168 | Amiot | Jan 1992 | A |
5153131 | Wolf et al. | Oct 1992 | A |
5310676 | Johansson et al. | May 1994 | A |
5330908 | Spaulding | Jul 1994 | A |
5376252 | Ekstrom et al. | Dec 1994 | A |
5416022 | Amiot | May 1995 | A |
5424209 | Kearney | Jun 1995 | A |
5437998 | Schwarz et al. | Aug 1995 | A |
5451524 | Coble et al. | Sep 1995 | A |
5462874 | Wolf et al. | Oct 1995 | A |
5565353 | Klebe et al. | Oct 1996 | A |
5589112 | Spaulding | Dec 1996 | A |
5593814 | Matsuda et al. | Jan 1997 | A |
5602028 | Minchinton | Feb 1997 | A |
5627070 | Gruenberg | May 1997 | A |
5637469 | Wilding et al. | Jun 1997 | A |
5641644 | Klebe | Jun 1997 | A |
5658797 | Bader | Aug 1997 | A |
5686301 | Falkenberg et al. | Nov 1997 | A |
5686304 | Codner | Nov 1997 | A |
5693537 | Wilson et al. | Dec 1997 | A |
5702941 | Schwarz | Dec 1997 | A |
5714384 | Wilson et al. | Feb 1998 | A |
5763261 | Gruenberg | Jun 1998 | A |
5763275 | Nagels et al. | Jun 1998 | A |
5763279 | Schwarz et al. | Jun 1998 | A |
5786215 | Brown et al. | Jul 1998 | A |
5793440 | Nakasaka et al. | Aug 1998 | A |
5801054 | Kiel et al. | Sep 1998 | A |
5866345 | Wilding et al. | Feb 1999 | A |
5882918 | Goffe | Mar 1999 | A |
5900361 | Klebe | May 1999 | A |
5912177 | Turner et al. | Jun 1999 | A |
5924583 | Stevens et al. | Jul 1999 | A |
5932315 | Lum et al. | Aug 1999 | A |
5942443 | Parce et al. | Aug 1999 | A |
6039897 | Lochhead et al. | Mar 2000 | A |
6048498 | Kennedy | Apr 2000 | A |
6096532 | Armstrong et al. | Aug 2000 | A |
6107085 | Coughlin et al. | Aug 2000 | A |
6153073 | Dubrow et al. | Nov 2000 | A |
6190913 | Singh | Feb 2001 | B1 |
6197575 | Griffith et al. | Mar 2001 | B1 |
6228635 | Armstrong et al. | May 2001 | B1 |
6238908 | Armstrong et al. | May 2001 | B1 |
6251343 | Dubrow et al. | Jun 2001 | B1 |
6274337 | Parce et al. | Aug 2001 | B1 |
6277642 | Mentzen et al. | Aug 2001 | B1 |
6297046 | Smith et al. | Oct 2001 | B1 |
6323022 | Chang et al. | Nov 2001 | B1 |
6326211 | Anderson et al. | Dec 2001 | B1 |
6403369 | Wood | Jun 2002 | B1 |
6410309 | Barbera-Guillem et al. | Jun 2002 | B1 |
6455310 | Barbera-Guillem et al. | Sep 2002 | B1 |
6465243 | Okada et al. | Oct 2002 | B2 |
6468792 | Bader | Oct 2002 | B1 |
6481648 | Zimmermann | Nov 2002 | B1 |
6495104 | Unno et al. | Dec 2002 | B1 |
6518035 | Ashby et al. | Feb 2003 | B1 |
6534013 | Kennedy | Mar 2003 | B1 |
6548263 | Kapur et al. | Apr 2003 | B1 |
6551841 | Wilding et al. | Apr 2003 | B1 |
6555365 | Barbera-Guillem et al. | Apr 2003 | B2 |
6562616 | Toner et al. | May 2003 | B1 |
6569675 | Wall et al. | May 2003 | B2 |
6576458 | Sarem et al. | Jun 2003 | B1 |
6585744 | Griffith | Jul 2003 | B1 |
6585939 | Dapprich | Jul 2003 | B1 |
6593136 | Geiss | Jul 2003 | B1 |
6637463 | Lei et al. | Oct 2003 | B1 |
6648015 | Chow | Nov 2003 | B1 |
6653124 | Freeman | Nov 2003 | B1 |
6673595 | Barbera-Guillem | Jan 2004 | B2 |
6756019 | Dubrow et al. | Jun 2004 | B1 |
6759245 | Toner et al. | Jul 2004 | B1 |
6794184 | Mohr et al. | Sep 2004 | B1 |
6811752 | Barbera-Guillem | Nov 2004 | B2 |
6821772 | Barbera-Guillem | Nov 2004 | B2 |
6846668 | Garman et al. | Jan 2005 | B1 |
6857449 | Chow | Feb 2005 | B1 |
6908767 | Bader | Jun 2005 | B2 |
6915679 | Chien et al. | Jul 2005 | B2 |
6969166 | Clark et al. | Nov 2005 | B2 |
7005292 | Wilding et al. | Feb 2006 | B2 |
7018830 | Wilding et al. | Mar 2006 | B2 |
7022518 | Feye | Apr 2006 | B1 |
7067263 | Parce et al. | Jun 2006 | B2 |
7141386 | Dunfield et al. | Nov 2006 | B2 |
7155344 | Parce et al. | Dec 2006 | B1 |
7160687 | Kapur et al. | Jan 2007 | B1 |
7171983 | Chien et al. | Feb 2007 | B2 |
7192769 | Pykett et al. | Mar 2007 | B2 |
7223371 | Hayenga et al. | May 2007 | B2 |
7343248 | Parce et al. | Mar 2008 | B2 |
7745209 | Martin et al. | Jun 2010 | B2 |
7919319 | Jervis et al. | Apr 2011 | B2 |
8257964 | Hung et al. | Sep 2012 | B2 |
8673625 | Hung et al. | Mar 2014 | B2 |
8709790 | Hung et al. | Apr 2014 | B2 |
9206384 | Lee et al. | Dec 2015 | B2 |
20020039785 | Schroeder et al. | Apr 2002 | A1 |
20020108860 | Staats | Aug 2002 | A1 |
20020108868 | Fairbourn et al. | Aug 2002 | A1 |
20020110905 | Barbera-Guillem et al. | Aug 2002 | A1 |
20020177221 | Nishiguchi et al. | Nov 2002 | A1 |
20030008388 | Barbera-Guillem et al. | Jan 2003 | A1 |
20030008389 | Carll | Jan 2003 | A1 |
20030030184 | Kim et al. | Feb 2003 | A1 |
20030040104 | Barbera-Guillem | Feb 2003 | A1 |
20030124623 | Yager et al. | Jul 2003 | A1 |
20030143727 | Chang | Jul 2003 | A1 |
20030156992 | Anderson et al. | Aug 2003 | A1 |
20030211012 | Bergstrom et al. | Nov 2003 | A1 |
20040029266 | Barbera-Guillem | Feb 2004 | A1 |
20040043481 | Wilson | Mar 2004 | A1 |
20040072278 | Chou et al. | Apr 2004 | A1 |
20040096960 | Burd Mehta et al. | May 2004 | A1 |
20040132175 | Vetillard et al. | Jul 2004 | A1 |
20040202579 | Larsson et al. | Oct 2004 | A1 |
20040229349 | Daridon | Nov 2004 | A1 |
20040238484 | Le Pioufle et al. | Dec 2004 | A1 |
20050009179 | Gemmiti et al. | Jan 2005 | A1 |
20050019213 | Kechagia et al. | Jan 2005 | A1 |
20050032208 | Oh et al. | Feb 2005 | A1 |
20050072946 | Studer et al. | Apr 2005 | A1 |
20050101009 | Wilson et al. | May 2005 | A1 |
20050106717 | Wilson et al. | May 2005 | A1 |
20050169962 | Bhatia et al. | Aug 2005 | A1 |
20050214173 | Facer et al. | Sep 2005 | A1 |
20050221373 | Enzelberger et al. | Oct 2005 | A1 |
20050260745 | Domansky et al. | Nov 2005 | A1 |
20050266582 | Modlin et al. | Dec 2005 | A1 |
20060003436 | DiMilla et al. | Jan 2006 | A1 |
20060031955 | West et al. | Feb 2006 | A1 |
20060112438 | West et al. | May 2006 | A1 |
20060121606 | Ito et al. | Jun 2006 | A1 |
20060136182 | Vacanti et al. | Jun 2006 | A1 |
20060141617 | Desai et al. | Jun 2006 | A1 |
20060154361 | Wikswo et al. | Jul 2006 | A1 |
20060166354 | Wikswo et al. | Jul 2006 | A1 |
20060199260 | Zhang et al. | Sep 2006 | A1 |
20070026516 | Martin et al. | Feb 2007 | A1 |
20070084706 | Takayama et al. | Apr 2007 | A1 |
20070090166 | Takayama et al. | Apr 2007 | A1 |
20070122314 | Strand et al. | May 2007 | A1 |
20070128715 | Vukasinovic et al. | Jun 2007 | A1 |
20070264705 | Dodgson | Nov 2007 | A1 |
20070275455 | Hung et al. | Nov 2007 | A1 |
20080038713 | Gao et al. | Feb 2008 | A1 |
20080085556 | Graefing et al. | Apr 2008 | A1 |
20080176318 | Wilson et al. | Jul 2008 | A1 |
20080194012 | Lee et al. | Aug 2008 | A1 |
20080227176 | Wilson | Sep 2008 | A1 |
20080233607 | Yu et al. | Sep 2008 | A1 |
20090023608 | Hung et al. | Jan 2009 | A1 |
20090123961 | Meyvantsson et al. | May 2009 | A1 |
20090148933 | Battrell et al. | Jun 2009 | A1 |
20090203126 | Hung et al. | Aug 2009 | A1 |
20100151571 | Vukasinovic et al. | Jun 2010 | A1 |
20100196908 | Opalsky et al. | Aug 2010 | A1 |
20100234674 | Wheeler et al. | Sep 2010 | A1 |
20120003732 | Hung et al. | Jan 2012 | A1 |
20120164036 | Stern et al. | Jun 2012 | A1 |
20130059322 | Hung et al. | Mar 2013 | A1 |
20130081757 | Hung et al. | Apr 2013 | A1 |
20130090268 | Hung et al. | Apr 2013 | A1 |
20130171679 | Lee et al. | Jul 2013 | A1 |
20130171682 | Hung et al. | Jul 2013 | A1 |
20140057311 | Kamm et al. | Feb 2014 | A1 |
20140099705 | Hung et al. | Apr 2014 | A1 |
20140287489 | Lee et al. | Sep 2014 | A1 |
Number | Date | Country |
---|---|---|
19948087 | May 2001 | DE |
0155237 | Sep 1985 | EP |
0725134 | Aug 1996 | EP |
0890636 | Jan 1999 | EP |
1539263 | Jan 1979 | GB |
9115570 | Oct 1991 | WO |
0056870 | Sep 2000 | WO |
0060352 | Oct 2000 | WO |
0078932 | Dec 2000 | WO |
0192462 | Dec 2001 | WO |
03085080 | Oct 2003 | WO |
03098218 | Nov 2003 | WO |
2004059299 | Jul 2004 | WO |
2004106484 | Dec 2004 | WO |
2005035728 | Apr 2005 | WO |
2007008606 | Jan 2007 | WO |
2007008609 | Jan 2007 | WO |
2009089189 | Jul 2009 | WO |
2009102453 | Aug 2009 | WO |
Entry |
---|
Notice of Allowance mailed Dec. 22, 2014 in co-pending U.S. Appl. No. 12/348,907. |
Office Action mailed Nov. 6, 2014, in co-pending U.S. Appl. No. 13/436,992. |
Office Action mailed Oct. 27, 2014 in co-pending U.S. Appl. No. 13/761,130. |
Final Rejection mailed Apr. 11, 2014 in co-pending U.S. Appl. No. 13/436,992. |
Office Action mailed Mar. 6, 2014 in co-pending U.S. Appl. No. 13/692,869. |
Final Rejection mailed Apr. 4, 2014 in co-pending U.S. Appl. No. 11/994,997. |
International Preliminary Report on Patentability mailed Jun. 12, 2014 in co-pending PCT application No. PCT/US2012/067632. |
Engineering Aspects of Food Biotechnology, Chapter 5, CRC Press: Boca Raton, FL, 2004, copyright 2014, p. 127, “Meet the Stem Cells; Production of Cultured Meat from a Stem Cell Biology Perspective”, Brinkhof, et al., 3 pages. |
Office Action mailed May 13, 2014 in co-pending U.S. Appl. No. 13/011,857. |
Notice of Allowance mailed Jul. 2, 2014 in co-pending U.S. Appl. No. 13/692,869. |
Final Rejection mailed Jun. 25, 2014 in co-pending U.S. Appl. No. 13/761,130. |
Extended European Search Report mailed Apr. 3, 2012 in European patent application No. EP 06786499. |
International Search Report and Written Opinion mailed Apr. 9, 2009 in PCT application No. PCT/US06/26364 (corresponding to U.S. Appl. No. 11/994,997). |
International Search Report and Written Opinion mailed Jul. 30, 2009 in PCT application No. PCT/US2009/030168. |
Extended European Search report mailed Oct. 21, 2013 in European patent application No. EP 09701350. |
International Search Report mailed May 14, 2013 in PCT application No. PCT/US2013/024999. |
International Search Report mailed Mar. 19, 2013 in PCT application No. PCT/US2012/067632. |
Cellasic Corporation, Onix Application Note, “Microincubator for long term live cell microscopy”, Feb. 3, 2012, pp. 1-4. |
Lab Chip, 2005, vol. 5, No. 4, pp. 401-406, published by the Royal Society of Chemistry, “Human neural stem growth and differentiation in a gradient-generating microfluidic device”, Chung, et al. |
Biotechnology and Bioengineering, vol. 89, No. 1, Jan. 5, 2005, pp. 1-8, “Continuous Perfusion Microfluidic Cell Culture Array for High-Throughput Cell-Based Assays”, Hung, et al. |
Lab Chip, 2008, vol. 8, No. 1, pp. 34-57, published by the Royal Society of Chemistry, “Biomolecular gradients in cell culture systems”, Keenan, et al. |
Biotechnology and Bioengineering, vol. 97, No. 5, Aug. 1, 2007, pp. 1340-1346, “An Artificial Liver Sinusoid With a Microfluidic Endothelial-Like Barrier for Primary Hepatocyte Culture”, Lee, et al. |
Lab Chip, 2009, vol. 9, No. 1, pp. 164-166, published by the Royal Society of Chemistry, “Dynamic cell culture: a microfluidic function generator for live cell microscopy”, Lee, et al. |
Journal of the Association for Laboratory Automation (JALA), 2007, vol. 12, No. 6, pp. 363-367, “Microfluidic System for Automated Cell-Based Assays”, Lee, et al. |
Biomaterials, 2008, vol. 29, No. 22, pp. 3237-3244, “A gel-free 3D microfluidic cell culture system”, Ong, et al. |
Office Action mailed Apr. 25, 2013 in corresponding U.S. Appl. No. 13/602,328. |
Notice of Allowance mailed Oct. 28, 2013 in corresponding U.S. Appl. No. 13/602,328. |
Office Action mailed Jun. 17, 2010 in co-pending U.S. Appl. No. 12/019,857. |
Final Rejection mailed Feb. 28, 2011 in co-pending U.S. Appl. No. 12/019,857. |
Office Action mailed Sep. 15, 2011 in co-pending U.S. Appl. No. 12/019,857. |
Final Rejection mailed May 31, 2012 in co-pending U.S. Appl. No. 12/019,857. |
Office Action—Restriction—mailed Jul. 13, 2011 in co-pending U.S. Appl. No. 12/348,907. |
Office Action mailed Dec. 23, 2011 in co-pending U.S. Appl. No. 12/348,907. |
Final Rejection mailed Sep. 17, 2012 in co-pending U.S. Appl. No. 12/348,907. |
Office Action Nov. 28, 2012 in co-pending U.S. Appl. No. 13/011,857. |
Final Rejection mailed Aug. 14, 2013 in co-pending U.S. Appl. No. 13/011,857. |
Office Action—Restriction—mailed Feb. 22, 2013 in co-pending U.S. Appl. No. 13/436,992. |
Office Action mailed Sep. 6, 2013 in co-pending U.S. Appl. No. 13/436,992. |
Office Action—Restriction—mailed Oct. 16, 2013 in co-pending U.S. Appl. No. 13/692,869. |
Office Action—Restriction—mailed Oct. 7, 2013 in co-pending U.S. Appl. No. 13/761,130. |
Office Action—Restriction—mailed Mar. 9, 2011 in co-pending U.S. Appl. No. 11/994,997. |
Office Action mailed Jul. 18, 2011 in co-pending U.S. Appl. No. 11/994,997. |
Final Rejection mailed Feb. 8, 2012 in co-pending U.S. Appl. No. 11/994,997. |
Office Action mailed Sep. 11, 2013 in co-pending U.S. Appl. No. 11/994,997. |
Office Action mailed Feb. 22, 2013 in corresponding U.S. Appl. No. 13/602,331. |
Notice of Allowance mailed Nov. 13, 2013 in corresponding U.S. Appl. No. 13/602,331. |
Lab on a Chip, 2007, vol. 7, pp. 763-769, “A hydrogel-based microfluidic device for the studies of directed cell migration”, Cheng, et al. |
Lab on a Chip, 2009, vol. 9, p. 1797-1800, “Selective and tunable gradient device for cell culture and chemotaxis study”, Kim, et al. |
Biomed Microdevices (2008), vol. 10, pp. 499-507, “Microfluidic switching system for analyzing chemotaxis responses of wortmannin-inhibited HL-60 cells”, Liu, et al. |
Lab on a Chip, 2007, vol. 7, pp. 1673-1680, “Gradient generation by an osmotic pump and the behavior of human mesenchymal stem cells under the fetal bovine serum concentration gradient”, Park, et al. |
Notice of Allowance mailed Jan. 13, 2014 in corresponding U.S. Appl. No. 13/602,328. |
Notice of Allowance mailed Dec. 23, 2013 in corresponding U.S. Appl. No. 13/602,331. |
Office Action mailed Dec. 31, 2013 in co-pending U.S. Appl. No. 13/761,130. |
Lab Chip, 2005, vol. 5, pp. 44-48, “A novel high aspect ratio microfluidic design to provide a stable and uniform microenvironment for cell growth in a high throughput mammalian cell culture array”, Hung, et al. |
Office Action mailed Jan. 26, 2015 in co-pending U.S. Appl. No. 11/994,997. |
Optics Express, vol. 14, No. 13, Jun. 2006, pp. 6253-6256, “Fabrication of polymer microlens arrays using capillary forming with a soft mold of micro-holes array and UV-curable polymer”, Chang, et al. |
Lab Chip, 2007, vol. 7, pp. 641-643, published by the Royal Society of Chemistry, “Rapid fabrication of microchannels using microscale plasma activated templating (uPLAT) generated water molds”, Chao, et al. |
J. Biochem., vol. 130, pp. 367-376, (2001), “A Method for Micrometer Resolution Patterning of Primary Culture Neurons for SPM Analysis”, Degenaar, et al. |
Lab Chip, 2003, vol. 3, pp. 318-323, published by the the Royal Society of Chemistry, “Fabrication of microfluidic mixers and artificial vasculatures using a high-brightness diode-pumped Nd: YAG laser direct write method”, Lim, et al. |
Angew. Chem. Int. Ed., 2004, vol. 43, pp. 1531-1536, “Minimal Functional Model of Hemostasis in a Biomimetic Microfluidic System”, Runyon, et al. |
Biomedical Microdevices, 2003, vol. 5, No. 3, pp. 235-244, “Microfluidic Patterning of Cellular Biopolymer Matrices for Biomimetic 3-D Structures”, Tan, et al. |
Office Action mailed Oct. 7, 2014 in co-pending U.S. Appl. No. 12/019,857. |
Final Rejection mailed Oct. 20, 2014 in co-pending U.S. Appl. No. 13/011,857. |
Office Action mailed Sep. 15, 2014 in co-pending U.S. Appl. No. 14/081,314. |
Advisory Action mailed Jul. 24, 2014 in co-pending U.S. Appl. No. 11/994,997. |
Final Rejection mailed Mar. 23, 2015 in co-pending U.S. Appl. No. 13/436,992. |
Office Action mailed Jun. 19, 2015 in co-pending U.S. Appl. No. 14/221,615. |
Notice of Allowance mailed Jun. 22, 2015 in co-pending U.S. Appl. No. 11/994,997. |
Notice of Allowance mailed Apr. 27, 2015 in co-pending U.S. Appl. No. 12/019,857. |
Notice of Allowance mailed May 6, 2015 in co-pending U.S. Appl. No. 13/761,130. |
Notice of Allowance mailed May 4, 2015 in co-pending U.S. Appl. No. 14/081,314. |
Notice of Allowance mailed Jul. 31, 2015 in co-pending U.S. Appl. No. 13/692,869. |
Notice of Allowance mailed Aug. 4, 2015 in co-pending U.S. Appl. No. 13/761,130. |
Notice of Allowance mailed Aug. 24, 2015 in co-pending U.S. Appl. No. 14/081,314. |
European communication dated Jul. 28, 2015 in co-pending European patent application No. 12852539.1. |
Notice of Allowance mailed Oct. 13, 2015 in co-pending U.S. Appl. No. 12/348,907. |
Office action mailed Oct. 6, 2015 in co-pending U.S. Appl. No. 13/011,857. |
Notice of Allowance mailed Dec. 10, 2015 in co-pending U.S. Appl. No. 12/019,857. |
Office action mailed Nov. 20, 2015 in co-pending U.S. Appl. No. 13/436,992. |
Notice of Allowance mailed Jan. 6, 2016 in co-pending U.S. Appl. No. 14/221,615. |
Japanese communication, with English translation, dated Nov. 17, 2015 in co-pending Japanese patent application No. 2015-503203. |
Keenan et al., “A new method for studying gradient-induced neutrophil desensitization based on an open microfluidic chamber”, Lab Chip, 2010, vol. 10, pp. 116-122. |
Lee et al., “Microfluidic Systems for Live Cell Imaging”, Methods in Cell Biology, 2011, vol. 102, pp. 77-103. |
Notice of Allowance mailed Mar. 31, 2016 in co-pending U.S. Appl. No. 12/019,857. |
Notice of Allowance mailed Jan. 20, 2016 in co-pending U.S. Appl. No. 12/348,907. |
Final rejection mailed Mar. 11, 2016 in co-pending U.S. Appl. No. 13/436,992. |
Notice of Allowance mailed Feb. 4, 2016 in co-pending U.S. Appl. No. 13/761,130. |
Notice of Allowance mailed Feb. 22, 2016 in co-pending U.S. Appl. No. 14/081,314. |
Notice of Allowance mailed Apr. 7, 2016 in co-pending U.S. Appl. No. 13/011,857. |
Notice of Allowance mailed Apr. 4, 2016 in co-pending U.S. Appl. No. 14/221,615. |
Number | Date | Country | |
---|---|---|---|
20140090735 A1 | Apr 2014 | US |
Number | Date | Country | |
---|---|---|---|
60756399 | Jan 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11648207 | Dec 2006 | US |
Child | 13602328 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13602328 | Sep 2012 | US |
Child | 14053688 | US |